Reference number : 172-2020-2021-Q1 - 950747, amendment number : , agreement type : G, recipient legal name : Nicoya Lifesciences Inc, recipient country : CA, recipient province : ON, recipient city : Kitchener|Kitchener, recipient postal code : N2G 2K4, program name english : Innovative Solutions Canada, program name french : Programme Solutions innovatrices Canada, program purpose english : Fuel the development and adoption of technological innovation in Canada, program purpose french : Stimuler le développement  et l'adoption de l'innovation technologique au Canada, agreement title english : Atlas:  Point-of-Care COVID-19 Diagnostic ELISA Powered by Digital Microfluidics, agreement title french : Atlas : Diagnostic ELISA pour la COVID-19 au point de service grâce à la technologie microfluidique numérique., agreement number : 950747, agreement value : 299190.0, agreement start date : 2020-06-05, agreement end date : 2020-08-28, description english : COVID-19 Challenge - Point of Care and Home Diagnostic Kit for COVID-19, description french : Défi COVID-19 - Trousse de diagnostic au point de service et à domicile pour le COVID-19, expected results english : Grow Canadian companies through direct funding to support early stage, pre-commercial research and development, late stage prototypes, and to accelerate commercialization., expected results french : Faire croître les sociétés canadiennes au moyen de financement direct versé pour soutenir la recherche-développement (R-D) précommerciale à un stade précoce et les prototypes à un stade avancé et en accélérer la commercialisation., additional information english : nan, additional information french : nan, owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada